MLL(MixedLineageLeukemia)isaproto-oncogenethatismutatedinavarietyofacuteleukemias.MLLisproteolyticallyprocessedinto2fragments,MLLNandMLLC,thatdisplayoppositetranscriptionalproperties.ProcessedMLLNandMLLC

associatewitheachotherviaN-terminalandC-terminalintramolecularinteractiondomains.MLLprocessingoccursrapidlyaftertranslationandisfollowedby

phosphorylationofMLLC.MLLNdisplays

transcriptionalrepressionactivity,whereasMLLChasstrongtranscriptionalactivationproperties.Leukemia-associatedMLLfusionproteinslacktheMLLprocessingsites,donotundergocleavage,andareunabletointeractwithMLLC.These

observationssuggestthatposttranslationalmodificationsofMLLmaybeinvolvedinregulatingMLLactivityasatranscriptionfactor,andthisaspectofitsfunctionisperturbedbyleukemogenicfusions.

ThisantibodyrecognizeshumanandmouseMLLN.

Immunoblotting:useat2ug/ml.Abandof

~300kDaisdetected.

K562cellnuclearextractwith#34041at2ug/ml.

Immunoprecipitation:use2-10ugper500ul(1-3mg/ml)ofcelllysate.

Thesearerecommendedconcentrations.Endusersshoulddetermineoptimalconcentrationsfortheirapplications.

Positivecontrol:K562celllysate.

DiluteinPBSormediumthatisidenticaltothatusedintheassaysystem.

Thisantibodyisstableforatleastone(1)yearat-20oC.Avoidmultiplefreeze-thawcycles.

YokoyamaAetal.2002Blood100:3710-

3718.

YokoyamaAetal.2005Cell123:207-218.

Forinvitroinvestigationaluseonly.Notintendedfordiagnosticortherapeuticapplications.

美国QED Bioscience 公司（www.qedbio.com）是专业的抗体公司，有20年的历史，是世界著名的抗体生产商。QED生物科技为科研客户提供优质的单克隆和多克隆抗体产品。 是一家提供全面服务的并提供额外服务的公司，能提供超过1500的单克隆和多克隆抗体的用于多领域的研究。